Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01483378
First received: November 18, 2011
Last updated: August 7, 2013
Last verified: August 2013

November 18, 2011
August 7, 2013
January 2012
February 2012   (final data collection date for primary outcome measure)
Answers to Survey Questions [ Time Frame: January 9, 2012 to February 12, 2012 ] [ Designated as safety issue: No ]
All enrolled patients completed a survey of baseline characteristics, eligibility for the herpes zoster vaccine, and attitudes regarding herpes zoster vaccination. The survey results from patients who agreed to receive the herpes zoster vaccine were compared to the results of patients who declined to be vaccinated.
Change in proportion of eligible patients who are vaccinated after 1 year [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Assessed by physician survey. The primary comparison will focus on the differences in the changes from baseline in the mean proportions of patients vaccinated in the intervention groups compared to the no intervention groups. Results will be presented as self-reported vaccination rates obtained from baseline and 1 year follow up surveys.
Complete list of historical versions of study NCT01483378 on ClinicalTrials.gov Archive Site
Not Provided
  • Correlation between physician characteristics, provider setting, and perceived barriers to vaccination and implemented interventions [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Assessed by physician survey. Statistical analysis of baseline and 1 year follow-up survey results regarding differences in physician characteristics, provider setting, and perceived barriers to vaccination between sites that received interventions and sites that did not receive interventions. Results will be presented as differences in survey answers.
  • Patient characteristics associated with vaccination success [ Time Frame: From date of recruitment until the date of first 100 patients are enrolled in Part 2, an expected period of 2 months ] [ Designated as safety issue: No ]
    Assessed by patient survey. Survey of patient characteristics among patients who agreed to vaccination following screening by ophthalmologists compared with patients who decline vaccination. Results will be presented as differences in survey answers.
Not Provided
Not Provided
 
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in the General Eye Clinic.

Patient vaccination behaviors will be assessed after 100 doses of the Zostavax vaccine are provided to underserved patients screened by ophthalmologists at the General Eye Clinic at a public hospital that does not normally provide the vaccine. A nurse will be at the clinic to administer the vaccine. Patients will be contacted by phone 1 month later and seen within 3 months in the Eye Clinic to determine whether there were any side effects.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Herpes Zoster
Other: Choosing to receive the vaccine
  • Subjects who received the vaccine
    Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
    Intervention: Other: Choosing to receive the vaccine
  • No Intervention: Subjects who declined the vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
170
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 60 years of age or older
  • Absence of evidence of immune compromise in the medical record
  • Ability to speak and read English, Spanish or Chinese and give informed consent

Exclusion Criteria:

  • Vulnerable patients, including the cognitively impaired, prisoners and employee
  • FDA contraindications for Zostavax vaccine
Both
60 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01483378
11-02029
Yes
New York University School of Medicine
New York University School of Medicine
Merck Sharp & Dohme Corp.
Not Provided
New York University School of Medicine
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP